9606L • Psychedelic-Informed Practice: Ethics and Professional Boundaries

Table of Contents

9606L • Psychedelic-Informed Practice: Ethics and Professional Boundaries

How to Receive Credit

Course Overview

Audience

Accreditations & Approvals

Designations of Credit

Individual State Behavioral Health Approvals

Course Objective

Learning Objectives

Faculty

Faculty Disclosure

Division Planners

Division Planners Disclosure

Director of Development and Academic Affairs

Director Disclosure Statement

About the Sponsor

Disclosure Statement

Implicit Bias in Health Care

1. INTRODUCTION

2. WEBINAR

3. SLIDES

Works Cited

9606L • Psychedelic-Informed Practice: Ethics and Professional Boundaries

Peter H. Addy, PhD

www.netce.com

Copyright © 2026 NetCE, All rights reserved.

This live event takes place Saturday, September 19, 11:30 am-1:30 pm EDT (8:30 am-10:30 am PDT).

As psychedelic use becomes increasingly prevalent and legal access expands, mental health professionals urgently need guidance on ethical practice boundaries. This course prepares clinicians to competently support clients who use psychedelics independently or seek integration support without crossing into illegal facilitation or exceeding scope of practice.

The course distinguishes between psychedelic therapy (providing or facilitating experiences) and psychedelic-informed practice (supporting clients who use substances independently). Drawing on clinical case studies, participants develop practical frameworks for responding when clients disclose psychedelic use, creating therapeutic environments that invite openness without endorsement, and implementing harm reduction approaches that respect client autonomy while maintaining professional boundaries.

9606L • Psychedelic-Informed Practice: Ethics and Professional Boundaries

Education Category. Webinars

Release Date. 07/25/2026

Expiration Date. 09/30/2026

How to Receive Credit

To complete this course for continuing education credit please go to http://www.netce.com/course/3599 in your browser.

For assistance with receiving continuing education credit, please contact us at help@netce.com.

Course Overview

This live event takes place Saturday, September 19, 11:30 am-1:30 pm EDT (8:30 am-10:30 am PDT).

As psychedelic use becomes increasingly prevalent and legal access expands, mental health professionals urgently need guidance on ethical practice boundaries. This course prepares clinicians to competently support clients who use psychedelics independently or seek integration support without crossing into illegal facilitation or exceeding scope of practice.

The course distinguishes between psychedelic therapy (providing or facilitating experiences) and psychedelic-informed practice (supporting clients who use substances independently). Drawing on clinical case studies, participants develop practical frameworks for responding when clients disclose psychedelic use, creating therapeutic environments that invite openness without endorsement, and implementing harm reduction approaches that respect client autonomy while maintaining professional boundaries.

Audience

This live webinar is designed for therapists, counselors, social workers, psychologists, and other mental health professionals encountering clients with psychedelic experiences.

Accreditations & Approvals

NetCE has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 6361. Programs that do not qualify for NBCC credit are clearly identified. NetCE is solely responsible for all aspects of the programs. As a Jointly Accredited Organization, NetCE is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. NetCE is accredited by the International Accreditors for Continuing Education and Training (IACET). NetCE complies with the ANSI/IACET Standard, which is recognized internationally as a standard of excellence in instructional practices. As a result of this accreditation, NetCE is authorized to issue the IACET CEU. NetCE is recognized by the New York State Education Department's State Board for Mental Health Practitioners as an approved provider of continuing education for licensed mental health counselors #MHC-0021. This course is considered live online by the New York State Board of Mental Health Counseling. NetCE is recognized by the New York State Education Department's State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0033. This course is considered live online, as defined by the New York State Board for Social Work. Materials that are included in this course may include interventions and modalities that are beyond the authorized practice of licensed master social work and licensed clinical social work in New York. As a licensed professional, you are responsible for reviewing the scope of practice, including activities that are defined in law as beyond the boundaries of practice for an LMSW and LCSW. A licensee who practices beyond the authorized scope of practice could be charged with unprofessional conduct under the Education Law and Regents Rules. NetCE is recognized by the New York State Education Department's State Board for Mental Health Practitioners as an approved provider of continuing education for licensed marriage and family therapists. #MFT-0015. This course is considered live online by the New York State Board of Marriage and Family Therapy. NetCE is recognized by the New York State Education Department's State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0240. This course is considered live online by the New York State Board for Psychology.

Designations of Credit

NetCE designates this live event activity for 2 continuing education clock hours. NetCE designates this live event continuing education activity for 2 NBCC clock hour(s). Social workers participating in this intermediate to advanced course will receive 2 Clinical continuing education clock hours. NetCE is authorized by IACET to offer 0.2 CEU(s) for this program. NetCE designates this live continuing education activity for 2 credit(s).

Individual State Behavioral Health Approvals

In addition to states that accept ASWB, NetCE is approved as a provider of continuing education by the following state boards: Alabama State Board of Social Work Examiners, Provider #0515; Florida Board of Clinical Social Work, Marriage and Family Therapy and Mental Health Counseling, CE Broker Provider #50-2405; Illinois Division of Professional Regulation for Social Workers, License #159.001094; Illinois Division of Professional Regulation for Licensed Professional and Clinical Counselors, License #197.000185; Illinois Division of Professional Regulation for Marriage and Family Therapists, License #168.000190;

Course Objective

The purpose of this course is to provide behavioral health professionals with the knowledge and skills necessary to effectively treat clients who use psychedelic substances.

Learning Objectives

Upon completion of this course, you should be able to:

1. Identify client safety factors, contraindications, and readiness when clients disclose psychedelic use.

2. Apply evidence-based harm reduction interventions that respect client autonomy.

Faculty

Peter H. Addy, PhD, is a licensed psychotherapist, approved clinical supervisor, and ketamine-assisted psychotherapist with a PhD in clinical psychology and 15 years of experience in psychedelic science and consciousness research. He conducted pioneering research on psychedelics at Yale University, where he co-founded the Yale Psychedelic Science Group and studied atypical psychedelic substances. Dr. Addy has authored numerous scientific articles and book chapters on psychedelics, substance use treatment, and transpersonal psychology and is an internationally recognized speaker on psychedelic science and clinical applications. He recently founded Psychedelic Affirming Education, which provides psychedelic-informed professional training for mental health clinicians.

Faculty Disclosure

Contributing faculty, Peter H. Addy, PhD, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.

Division Planners

Kimberly Byrd, EdD, PMSW

Scott Deatherage, PhD

Division Planners Disclosure

The division planners have disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.

Director of Development and Academic Affairs

Sarah Campbell

Director Disclosure Statement

The Director of Development and Academic Affairs has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.

About the Sponsor

The purpose of NetCE is to provide challenging curricula to assist healthcare professionals to raise their levels of expertise while fulfilling their continuing education requirements, thereby improving the quality of healthcare.

Our contributing faculty members have taken care to ensure that the information and recommendations are accurate and compatible with the standards generally accepted at the time of publication. The publisher disclaims any liability, loss or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents. Participants are cautioned about the potential risk of using limited knowledge when integrating new techniques into practice.

Disclosure Statement

It is the policy of NetCE not to accept commercial support. Furthermore, commercial interests are prohibited from distributing or providing access to this activity to learners.

Implicit Bias in Health Care

The role of implicit biases on healthcare outcomes has become a concern, as there is some evidence that implicit biases contribute to health disparities, professionals' attitudes toward and interactions with patients, quality of care, diagnoses, and treatment decisions. This may produce differences in help-seeking, diagnoses, and ultimately treatments and interventions. Implicit biases may also unwittingly produce professional behaviors, attitudes, and interactions that reduce patients' trust and comfort with their provider, leading to earlier termination of visits and/or reduced adherence and follow-up. Disadvantaged groups are marginalized in the healthcare system and vulnerable on multiple levels; health professionals' implicit biases can further exacerbate these existing disadvantages.

Interventions or strategies designed to reduce implicit bias may be categorized as change-based or control-based. Change-based interventions focus on reducing or changing cognitive associations underlying implicit biases. These interventions might include challenging stereotypes. Conversely, control-based interventions involve reducing the effects of the implicit bias on the individual's behaviors. These strategies include increasing awareness of biased thoughts and responses. The two types of interventions are not mutually exclusive and may be used synergistically.

1. INTRODUCTION

Client exposure to and use of psychedelics is increasing, as evidenced by state legal offerings, municipal decriminalization, and expanding ketamine treatment options. Clinicians need to collaborate with clients to identify risks and potential benefits and provide professional and ethical care. Clinicians who understand the risks of psychedelic use will take all measures needed to ensure that clients receive harm reduction and have informed consent. This course will discuss the risks and potential benefits of psychedelic use and the clinician's role in caring for clients who use psychedelics. Clinicians require education and skills training about clients who use psychedelics, yet they may not receive sufficient education about this population. This updated CE training provides background information needed to increase clinician understanding of clients who use psychedelics and the responsibilities associated with caring for clients who use psychedelics.

2. WEBINAR

To see this media go to http://www.NetCE.com/activities/ using a browser that supports Adobe Flash.

3. SLIDES

The slides from this webinar are available here.

Works Cited

1. American Psychedelic Practitioners Association; BrainFutures. Professional Practice Guidelines for Psychedelic-Assisted Therapy. 1st ed. Published 2023. Accessed February 6, 2026. https://www.brainfutures.org/wp-content/uploads/2023/08/Professional-Practice-Guidelines-for-Psychedelic-Assisted-Therapy-Aug-2023.pdf.

2. Bathje GJ, Majeski E, Kudowor M. Psychedelic integration: an analysis of the concept and its practice. Front Psychol. 2022;13:824077.

3. Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30(12):1268-1278.

4. Chaves TV, Wilffert B, Sanchez ZM. Overdoses and deaths related to the use of ketamine and its analogues: a systematic review. Am J Drug Alcohol Abuse. 2023;49(2):141-150.

5. Dore J, Turnipseed B, Dwyer S, et al. Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J Psychoactive Drugs. 2019;51(2):189-198.

6. Drozdz SJ, Goel A, McGarr MW, et al. Ketamine assisted psychotherapy: a systematic narrative review of the literature. J Pain Res. 2022;15:1691-1706.

7. Fang S, Yang X, Zhang W. Efficacy and acceptability of psilocybin for primary or secondary depression: a systematic review and meta-analysis of randomized controlled trials. Front Psychiatry. 2024;15:1359088.

8. Food and Drug Administration. FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders. Published 2023. Accessed February 6, 2026. https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine.

9. Gukasyan N, Griffiths RR, Yaden DB, Antoine D, Nayak SM. Serotonergic antidepressant use is associated with weaker psilocybin effects. OSF Preprints. Published online 2022.

10. Kopra EI, Ferris JA, Winstock AR, Young AH, Rucker JJ. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. J Psychopharmacol. 2022;36(8):965-973.

11. McAlpine RG, Blackburne G, Kamboj SK. Development and psychometric validation of a novel scale for measuring "psychedelic preparedness." Sci Rep. 2024;14(1):3280.

12. McGuire AL, Cohen IG, Sisti D, et al. Developing an ethics and policy framework for psychedelic clinical care: a consensus statement. JAMA Netw Open. 2024;7(6):e2414650.

13. Modlin NL, Williamson V, Goodwin GM, et al. Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment. EClinicalMedicine. 2025;90:103692.

14. Nayak SM, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. Pharmacopsychiatry. 2021;54(5):240-245.

15. Neumann J, Dimov K, Azatsian K, Hofmann B, Gergs U. Effects of psilocin and psilocybin on human 5-HT4 serotonin receptors in atrial preparations of transgenic mice and humans. Life Sci. 2024;398:55-64.

16. Oregon Health Authority. Oregon psilocybin services data dashboard. Accessed January 14, 2026. https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Psilocybin-Data-Dashboard.aspx.

17. Palmer M, Maynard OM. Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience. Harm Reduct J. 2022;19(1):81.

18. Sabé M, Sulstarova A, Glangetas A, et al. Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Mol Psychiatry. 2025;30(3):1223-1255.

19. Simonsson O, Goldberg SB, Osika W, et al. Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms. Psychol Med. 2025;55:e99.

20. Vizgan G, Huamán M, Rychik K, Edeson M, Blaivas JG. Ketamine-induced uropathy: a narrative systemic review of surgical outcomes of reconstructive surgery. BJUI Compass. 2023;4(4):377-384.

21. Wsół A. Cardiovascular safety of psychedelic medicine: current status and future directions. Pharmacol Rep. 2023;75(6):1362-1380.

22. Yao Y, Guo D, Lu TS, et al. Efficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysis. Psychiatry Res. 2024;335:115886.